Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Nicolás A. Giraldo(AstraZeneca (Spain)), Janis M. Taube(Bloomberg (United States))
Journal for ImmunoTherapy of Cancer
October 1, 2018
10.1186/s40425-018-0404-0
Cited by 182

Related Papers

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k